Business Wire

AFFISE

10.5.2021 11:02:10 CEST | Business Wire | Press release

Share
Affise Launches New Attribution Chain Technology to Measure Advertising Results

Affise launched a new type of attribution chain technology to measure mobile advertising attribution without the previously required user device identifier for advertisers (IDFA). The removal of the IDFA results from Apple’s App Tracking Transparency (ATT) roll-out.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005320/en/

Initially expected in summer 2020 and later moved to 2021, the iOS14.5 release introduced the ATT policy, which from the moment of roll-out requires every app to get explicit permission from users to access their IDFA. In practical terms, requiring user opt-in eliminates the large part of data vital for end-user identification. Attribution platforms can no longer store and pass user information to an advertiser and back.

These terms leave advertisers with an insufficient amount of data to measure campaign performance and evaluate the efficiency of mobile ads. This could likely affect the efficiency of targeted ads and further decrease the revenue of app publishers.

To alleviate the impact and allow attribution and ad measurement, Apple introduced SKAdNetwork, a privacy-friendly method to measure mobile campaigns’ attribution on iOS apps. The other alternative supported by most MMPs is probabilistic attribution, which relies on the statistics and probability distribution of all the campaigns likely to have generated an install.

Affise announces privacy-enabled attribution chain to support redirects data transfer

Dmitrii Zotov, CTO of Affise, said: “The future of mobile attribution on iOS became the most debated issue and we got actively involved in implementing timely solutions that would allow advertisers and ad networks to attribute app installs. So far, we support both probabilistic attribution from all the MMPs and SKAdNetwork integration. Further, we want to ensure that conversion data will not be lost in a chain of attribution between publishers. Thus we release the privacy-enabled attribution chain, which helps determine conversion along the chain of publishers.”

Apple’s ATT policy may have severe implications on the whole industry, but user privacy is everything nowadays and we should expect major changes around this trend. Meanwhile, advertisers still need to measure conversions, work with traffic suppliers and correctly assign payouts, especially when working with multiple publishers in the chain. By losing the ability to correlate click and conversion, we also lose the ability to relay any past performance data to the publisher.

With MMPs’ restrictions to transfer data only at the source and sub-source level, Affise developed a solution that will support all redirect data transfer. The Affise attribution chain solution uses a particular format of integration macros to pass all the publisher’s data in a simple format.

The attribution chain method protects users’ privacy while ensuring a fair and accurate attribution process for advertising market players.

The macros include all the information needed by the network to determine campaign and traffic source. This means that multiple publishers in the attribution chain will have access to conversion data and will be able to successfully optimize their traffic, where advertisers can ensure the effectiveness of their performance campaigns.

About Affise

Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye